Financial News

Financial Report: Mylan

Revenues up 16% in the quarter boosted by European third party sales and acquisitions of Meda and Topicals Business

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mylan 2Q Revenues: $3.0 billion (+16%) 2Q Earnings: $297 million (+77%) YTD Revenues: $5.7 billion (+20%) YTD earnings: $363 million (+99%) Comments: North America segment third party sales were $1.3 billion, down 9%, with sales of EpiPen Auto-Injector down by approximately $172 million as a result of increased competition, the impact of the launch of the authorized generic and higher accrued governmental rebates. Europe segment third party net sales of $954.3 million, up 59%. Rest of World...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters